Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | ALPL | P05186 | 10/20 | 0.70 |
| ▸ | CA12 | O43570 | 5/20 | 0.70 |
| ▸ | RPA1 | P27694 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.57 |
| ▸ | MARS1 | P56192 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27639048 | 0.98 | TP53 (0.72) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL726574 | 0.85 | TP53 (1.00) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL22414089 | 0.84 | HDAC3 (0.53) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL4789868 | 0.84 | CCNC (0.54) | TP53ALPLCA12RPA1HDAC3 | |
| SCHEMBL31412652 | 0.83 | TP53 (0.65) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL1414100 | 0.82 | ALPL (1.00) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL1816813 | 0.81 | TP53 (0.73) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL23803931 | 0.81 | ALPL (0.73) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL3447352 | 0.81 | ALPL (1.00) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL645330 | 0.81 | ALPL (1.00) | TP53ALPLCA12RPA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903340-B | Substituted N-phenyl bipyrrolidine carboxamides and therapeutic use thereof | SANOFI AVENTIS | 2013-03-27 | — | — | CN | claimed |
| US-8252824-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2012-08-28 | — | — | US | claimed |
| CN-101903340-A | Substituted N-phenyl bipyrrolidine carboxamides and therapeutic use thereof | SANOFI AVENTIS | 2010-12-01 | — | — | CN | claimed |
| EP-2212283-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-04 | — | — | EP | claimed |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | claimed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | claimed |
| WO-2025045746-A1 | PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| EP-4308558-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-24 | — | — | EP | disclosed |
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | BANTAM PHARMACEUTICAL LLC (US) | 2021-09-09 | — | — | US | disclosed |
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200255448-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2020-08-13 | — | — | US | disclosed |
| US-10633393-B2 | Heterocyclic compounds as kinase inhibitors | Translational Drug Development (US) | 2020-04-28 | — | — | US | disclosed |
| CN-110382481-A | Heterocyclic compounds as kinase inhibitors | 转化药物开发有限责任公司 | 2019-10-25 | — | — | CN | disclosed |
| EP-2212283-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20090253745-A1 | MODULATORS OF OCULAR OXIDATIVE STRESS | SIRION THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253745-A1 | MODULATORS OF OCULAR OXIDATIVE STRESS | SIRION THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009070693-A2 | MODULATORS OF OCULAR OXIDATIVE STRESS | SIRION THERAPEUTICS, INC (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009052062-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| CN-1747949-A | Acyclic pyrazole compounds | PHARMACIA CORP (US) | 2006-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253745-A1 | MODULATORS OF OCULAR OXIDATIVE STRESS | GPX4, GPX1, ALDH1A2 | TP53 4638/4885ALPL 1540/4885CA12 2862/4885 |
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | TP53 2424/4885ALPL 4779/4885CA12 4180/4885 |
| US-20100173949-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | TP53 4059/4885ALPL 4778/4885CA12 3376/4885 |
| US-10633393-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | TP53 2424/4885ALPL 4779/4885CA12 4180/4885 |
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | TP53, MKI67, VHL | TP53 1/4885ALPL 4652/4885CA12 728/4885 |
| US-20200255448-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | TP53 2424/4885ALPL 4779/4885CA12 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.